Reyes Candau-Chacon

FDA investigator

Appears on 8 documents from 2012 to 2025, most often at sites in Switzerland. Most often cites general requirements (21 CFR 211.160).

8
Documents on file
4.8
Observations per 483
2012
First seen
2025
Most recent

What they cite most

From 37 observations

Activity by year

2012: 1, 2016: 3, 2018: 1, 2019: 2, 2025: 1

Where

Switzerland 3 · Austria 1 · Denmark 1 · Massachusetts 1 · New Jersey 1 · South Korea 1

Is Reyes Candau-Chacon coming to your site?

Our team writes custom reports before an inspection: what this investigator cites most, how they write it up, and how your site's history compares, in one brief you can circulate.

Ask about any investigator in Claude or ChatGPT with the AI connector.

Inspection history

8 documents, newest first
FirmOpen
483 Lonza AGOct 28, 2025 · Visp, Switzerland
483 AGC Biologics A/SNov 5, 2019 · Soeborg, Denmark
483 Lonza AGMar 29, 2019 · Visp, Switzerland
483 Immunomedics, Inc.Aug 14, 2018 · Morris Plains, New Jersey
483 Samsung Biologics Co., Ltd.Jun 22, 2016 · Incheon, South Korea
483 Sandoz GmbHMar 11, 2016 · Langkampfen, Austria
483 F. Hoffmann-La Roche AGJan 22, 2016 · Basel, Switzerland

About this profile

What does Reyes Candau-Chacon inspect?

Reyes Candau-Chacon appears on 8 documents on file covering 7 sites, most often in Switzerland.

What do they cite most often?

21 CFR 211.160 (general requirements), followed by 21 CFR 211.192 and 21 CFR 211.113.

Can I read the observations?

Each document page previews the opening words of every observation. The full documents are available to buy, one at a time or together.

How current is this profile?

The most recent document on file for Reyes Candau-Chacon is dated Oct 28, 2025.